Abou-Karam Nada, Bradford Chad, Lor Kajua B, Barnett Mitchell, Ha Michelle, Rizos Albert
Department of Pharmacy Services, Sharp Memorial Hospital, San Diego, CA, USA; Department of Clinical Sciences, Touro University California College of Pharmacy, Vallejo, CA, USA.
Department of Clinical Sciences, Touro University California College of Pharmacy, Vallejo, CA, USA.
SAGE Open Med. 2016 Feb 19;4:2050312116632426. doi: 10.1177/2050312116632426. eCollection 2016.
Readmission rate is increasingly being viewed as a key indicator of health system performance. Medication regimen complexity index scores may be predictive of readmissions; however, few studies have examined this potential association. The primary objective of this study was to determine whether medication regimen complexity index is associated with all-cause 30-day readmission after admission for heart failure, acute myocardial infarction, pneumonia, or chronic obstructive pulmonary disease.
This study was an institutional review board-approved, multi-center, case-control study. Patients admitted with a primary diagnosis of heart failure, acute myocardial infarction, pneumonia, or chronic obstructive pulmonary disease were randomly selected for inclusion. Patients were excluded if they discharged against medical advice or expired during their index visit. Block randomization was utilized for equal representation of index diagnosis and site. Discharge medication regimen complexity index scores were compared between subjects with readmission versus those without. Medication regimen complexity index score was then used as a predictor in logistic regression modeling for readmission.
Seven hundred and fifty-six patients were randomly selected for inclusion, and 101 (13.4%) readmitted within 30 days. The readmission group had higher medication regimen complexity index scores than the no-readmission group (p < 0.01). However, after controlling for demographics, disease state, length of stay, site, and medication count, medication regimen complexity index was no longer a significant predictor of readmission (odds ratio 0.99, 95% confidence interval 0.97-1.01) or revisit (odds ratio 0.99, 95% confidence interval 0.98-1.02).
There is little evidence to support the use of medication regimen complexity index in readmission prediction when other measures are available. Medication regimen complexity index may lack sufficient sensitivity to capture an effect of medication regimen complexity on all-cause readmission.
再入院率日益被视为卫生系统绩效的关键指标。药物治疗方案复杂性指数评分可能预测再入院情况;然而,很少有研究探讨这种潜在关联。本研究的主要目的是确定药物治疗方案复杂性指数与因心力衰竭、急性心肌梗死、肺炎或慢性阻塞性肺疾病入院后30天全因再入院是否相关。
本研究是一项经机构审查委员会批准的多中心病例对照研究。随机选取以心力衰竭、急性心肌梗死、肺炎或慢性阻塞性肺疾病为主要诊断入院的患者纳入研究。如果患者违反医嘱出院或在首次就诊期间死亡,则将其排除。采用区组随机化以确保各指标诊断和研究地点的均衡代表性。比较再入院患者与未再入院患者的出院药物治疗方案复杂性指数评分。然后将药物治疗方案复杂性指数评分用作再入院逻辑回归模型的预测指标。
随机选取756例患者纳入研究,其中101例(13.4%)在30天内再次入院。再入院组的药物治疗方案复杂性指数评分高于未再入院组(p<0.01)。然而,在控制了人口统计学、疾病状态、住院时间、研究地点和药物数量后,药物治疗方案复杂性指数不再是再入院(比值比0.99,95%置信区间0.97 - 1.01)或再次就诊(比值比0.99,95%置信区间0.98 - 1.02)的显著预测指标。
当有其他可用措施时,几乎没有证据支持使用药物治疗方案复杂性指数进行再入院预测。药物治疗方案复杂性指数可能缺乏足够的敏感性来捕捉药物治疗方案复杂性对全因再入院的影响。